Feedback / Questions
SNDX-5613 - Syndax Pharma
SNDX-5613: Top-line data from P2 portion of P1/2 AUGMENT-101 trial (NCT04065399) for AML in 2023
(Syndax)
-
Jan 20, 2022 -
Corporate Presentation
P2 data
•
Acute Myelogenous Leukemia • Hematological Malignancies • Oncology
https://ir.syndax.com/static-files/ec1ddcca-2728-4880-ae53-9900a088c844
Jan 20, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious